11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Protocol for a partially nested randomized controlled trial to evaluate the effectiveness of the Scleroderma Patient-centered Intervention Network Support Group Leader EDucation (SPIN-SSLED) Program

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Some people with rare diseases rely on peer-led support groups for disease-specific education and emotional and practical support. Systemic sclerosis (SSc), or scleroderma, is a rare autoimmune connective tissue disease. Many people with SSc cannot access support groups, and, when support groups exist, they may not be sustained due to challenges that could be addressed via leader training. The Scleroderma Patient-centered Intervention Network (SPIN), along with SSc patient organization partners, developed a training program for SSc patient support group leaders, the Scleroderma Support group Leader EDucation (SPIN-SSLED) Program. We recently completed a feasibility trial in which we successfully delivered the program to two groups of support group leaders who reported a high level of satisfaction with the program and its delivery. The primary objective of the full-scale SPIN-SSLED trial is to evaluate the effect of the program on support group leaders’ self-efficacy for carrying out their leadership role. Secondary objectives include evaluating effects on leader burnout, leader satisfaction (participation efficacy), and emotional distress.

          Methods/design

          The SPIN-SSLED trial is a pragmatic randomized controlled trial (RCT) in which 180 support group leaders will be randomly allocated to training groups of 6 participants each or to a waitlist control. We will use a partially nested RCT design to reflect dependence between individuals in training groups, but not in the waitlist control. Participants allocated to the training program will receive the 13-module SPIN-SSLED Program, delivered via webinar over the course of 3 months in weekly 60–90-min sessions. The primary outcome is leader self-efficacy, measured by the Scleroderma Support Group Leader Self-efficacy Scale post-intervention. Secondary outcomes are leader self-efficacy at 3 months post-intervention, and leader burnout, volunteer job satisfaction (participation efficacy), and emotional distress post-intervention and at 3 months post-intervention.

          Discussion

          The SPIN-SSLED trial will test whether a training program for SSc patient support group leaders increases the self-efficacy of group leaders to carry out leadership tasks. The program has the potential to significantly improve the effectiveness and sustainability of existing SSc support groups, to increase the number of available support groups, and to be adapted for other chronic diseases.

          Trial registration

          ClinicalTrials.gov, NCT03965780. Registered on 29 May 2019.

          Related collections

          Most cited references56

          • Record: found
          • Abstract: not found
          • Article: not found

          The PRECIS-2 tool: designing trials that are fit for purpose.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Problem-Based Learning: What and How Do Students Learn?

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Self-management interventions for chronic illness.

              An increasing number of interventions have been developed for patients to better manage their chronic illnesses. They are characterised by substantial responsibility taken by patients, and are commonly referred to as self-management interventions. We examine the background, content, and efficacy of such interventions for type 2 diabetes, arthritis, and asthma. Although the content and intensity of the programmes were affected by the objectives of management of the illness, the interventions differed substantially even within the three illnesses. When comparing across conditions, it is important to recognise the different objectives of the interventions and the complexity of the issues that they are attempting to tackle. For both diabetes and asthma, the objectives are concerned with the underlying control of the condition with clear strategies to achieve the desired outcome. By contrast, strategies to deal with symptoms of pain and the consequences of disability in arthritis can be more complex. The interventions that were efficacious provide some guidance as to the components needed in future programmes to achieve the best results. But to ensure that these results endure over time remains an important issue for self-management interventions.
                Bookmark

                Author and article information

                Contributors
                brett.thombs@mcgill.ca
                kyleneanneaguila@gmail.com
                ldyas@scleroderma.org
                carrier.marie.eve@gmail.com
                claire.fedoruk@gmail.com
                lhorwood@gmail.com
                mara.canedo.ayala@gmail.com
                maureen.sauve@gmail.com
                kwakkenbosl@gmail.com
                vmalcarne@sdsu.edu
                gelbaalbaki@gmail.com
                sandra.pelaez@mail.mcgill.ca
                kconnolly@scleroderma.org
                marie.hudson@mcgill.ca
                robert.platt@mcgill.ca
                Journal
                Trials
                Trials
                Trials
                BioMed Central (London )
                1745-6215
                12 December 2019
                12 December 2019
                2019
                : 20
                : 717
                Affiliations
                [1 ]ISNI 0000 0000 9401 2774, GRID grid.414980.0, Lady Davis Institute for Medical Research, , Jewish General Hospital, ; Montreal, QC Canada
                [2 ]ISNI 0000 0004 1936 8649, GRID grid.14709.3b, Department of Psychiatry, , McGill University, ; Montreal, QC Canada
                [3 ]ISNI 0000 0004 1936 8649, GRID grid.14709.3b, Department of Epidemiology, Biostatistics, and Occupational Health, , McGill University, ; Montreal, QC Canada
                [4 ]ISNI 0000 0004 1936 8649, GRID grid.14709.3b, Department of Medicine, , McGill University, ; Montreal, QC Canada
                [5 ]ISNI 0000 0004 1936 8649, GRID grid.14709.3b, Department of Psychology, , McGill University, ; Montreal, QC Canada
                [6 ]ISNI 0000 0004 1936 8649, GRID grid.14709.3b, Department of Educational and Counselling Psychology, , McGill University, ; Montreal, QC Canada
                [7 ]ISNI 0000 0004 1936 8649, GRID grid.14709.3b, Biomedical Ethics Unit, , McGill University, ; 4333 Cote Ste Catherine Road, Montreal, QC H3T 1E4 Canada
                [8 ]Scleroderma Foundation Michigan Chapter, Southfield, MI USA
                [9 ]Scleroderma Society of Ontario and Scleroderma Canada, Hamilton, ON Canada
                [10 ]ISNI 0000000122931605, GRID grid.5590.9, Department of Clinical Psychology, Behavioural Science Institute, , Radboud University, ; Nijmegen, the Netherlands
                [11 ]ISNI 0000 0004 1936 8796, GRID grid.430387.b, Department of Psychology, , San Diego State University, ; California, USA
                [12 ]San Diego Joint Doctoral Program in Clinical Psychology, San Diego State University/University of California, California, USA
                [13 ]ISNI 0000 0001 2181 0211, GRID grid.38678.32, Department of Psychology, , Université du Québec à Montréal, ; Montreal, QC Canada
                [14 ]GRID grid.453442.0, Scleroderma Foundation, ; Danvers, MA USA
                Author information
                http://orcid.org/0000-0002-5644-8432
                Article
                3747
                10.1186/s13063-019-3747-z
                6909446
                31831073
                b9b5b3c7-8c5f-44de-9bf7-9ce0c2deb899
                © The Author(s). 2019

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 30 July 2019
                : 23 September 2019
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100000024, Canadian Institutes of Health Research;
                Award ID: PJT-162126
                Funded by: FundRef http://dx.doi.org/10.13039/501100004489, Mitacs;
                Award ID: IT1356
                Funded by: Scleroderma Society of Ontario
                Award ID: N/A
                Categories
                Study Protocol
                Custom metadata
                © The Author(s) 2019

                Medicine
                patient education,peer support,feasibility trial,scleroderma,support groups,systemic sclerosis

                Comments

                Comment on this article